FDA Advisory Committee Backs Approval Of Orphan Drug Without Controlled Clinical Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Patient experience with Orphan Europe's Carbaglu proves convincing, but panelists suggest registry to collect long-term safety data.